FC
CGTX icon

FCA Corp’s Cognition Therapeutics CGTX Stock Holding History

FCA Corp’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.4K Hold
52,536
– – 0.01% 198
2026
Q1 		$39.9K Hold
52,536
– – 0.01% 186
2025
Q4 		$70.9K Hold
52,536
– – 0.02% 190
2025
Q3 		$70.9K Hold
52,536
– – 0.02% 188
2025
Q2 		$16.3K Buy
52,536
+1,065
+2% +$360 ﹤0.01% 181
2025
Q1 		$21.7K Hold
51,471
– – 0.01% 176
2024
Q4 		$36.1K Hold
51,471
– – 0.01% 179
2024
Q3 		$24.1K Hold
51,471
– – 0.01% 178
2024
Q2 		$85.4K Hold
51,471
– – 0.03% 174
2024
Q1 		$93.7K Hold
51,471
– – 0.03% 174
2023
Q4 		$95.2K Hold
51,471
– – 0.03% 170
2023
Q3 		$74.1K Hold
51,471
– – 0.03% 167
2023
Q2 		$94.2K Hold
51,471
– – 0.03% 165
2023
Q1 		$102K Buy
+51,471
New +$98.1K 0.04% 160

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

FCA Corp's CGTX Position: Q2 2026 in Review

FCA Corp held its Cognition Therapeutics (CGTX) position steady in Q2 2026 at 52,536 shares worth $60.4K. The position accounts for 0.01% of the portfolio, ranked #198.

FCA Corp first reported a position in CGTX in Q1 2023 and has held it in 14 quarters since. The position peaked at $102K in Q1 2023. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • FCA Corp held 52,536 shares of Cognition Therapeutics worth $60.4K as of Q2 2026.
  • FCA Corp left its Cognition Therapeutics share count unchanged in Q2 2026.
  • Cognition Therapeutics made up 0.01% of FCA Corp's portfolio in Q2 2026, its #198 holding.
  • FCA Corp first reported a position in Cognition Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • FCA Corp's Cognition Therapeutics position peaked at $102K in Q1 2023.
  • 66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on FCA Corp's 13F filing for Q2 2026, filed 11 Aug 2026.